Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis

Introduction and aim. Approximately 650,000 people in Brazil have chronic hepatitis C virus (HCV) infection. We evaluated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV) with/without ribavirin (RBV) in an open-label multicenter phase 3b trial in trea...

Full description

Bibliographic Details
Main Authors: Mario G. Pessoa, José V. Ramalho-Madruga, Katia Alves, Estevão P. Nunes, Hugo Cheinquer, Carlos E. Brandão-Mello, Maria C. Mendes-Correa, Maria L. Ferraz, Paulo R.A. Ferreira, Mário R. Álvares-da-Silva, Henrique S. Coelho, Evaldo S. Affonso-de-Araújo, Juvencio Furtado, Raymundo Parana, Giovanni Silva, Sara A. Lari, Li Liu, Rakesh Tripathi, Tami Pilot-Matias, Daniel E. Cohen, Nancy S. Shulman, Ana Martinelli
Format: Article
Language:English
Published: Elsevier 2018-11-01
Series:Annals of Hepatology
Subjects:
Chronic hepatits C
Direct-acting antivirals
Genotype 1
Advanced fibrosis
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119310580

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119310580

Similar Items